The beneficial impact of Hib vaccine on disease rates in New Zealand children

N Z Med J. 2002 Aug 9;115(1159):U122.

Abstract

Aim: To examine the impact of Haemophilus influenzae type b (Hib) vaccine on the burden of Haemophilus influenzae (Hi) disease in New Zealand children aged under five years (under-5s).

Methods: Analysis of national mortality, hospitalisation, laboratory, and notification data.

Results: The introduction of Hib vaccine in 1994 led to a 92% decline (95%CI = 89 94%) in the hospitalisation rate of Hi meningitis for under-5s (1995 2000 compared to 1988 1993). Pre-vaccine, the Hi meningitis hospitalisation rate was 27 per 100 000 in the under-5s and this declined to 2 per 100 000. Even though Hi meningitis declined in all ethnic groups (eg down to 3 per 100 000 among Maori), there was a worsening of equity with the proportion of children hospitalised with Hi meningitis who were Maori increasing from 23% to 40% of all cases. The rate of epiglottitis hospitalisations also declined substantially (by 94%, 95%CI = 89 - 96%).

Conclusions: Hib vaccination appears to be preventing at least 80 cases of meningitis and 30 cases of epiglottitis every year in under-5s in New Zealand. But the beneficial impact of Hib vaccination has been less for Maori and so there is a need for further improvements in immunisation coverage in those populations with the highest disease burdens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child, Preschool
  • Epiglottitis / epidemiology
  • Haemophilus Infections / epidemiology*
  • Haemophilus Infections / prevention & control
  • Haemophilus Vaccines*
  • Haemophilus influenzae type b*
  • Hospitalization / statistics & numerical data
  • Humans
  • Infant
  • Meningitis / epidemiology
  • New Zealand / epidemiology

Substances

  • Haemophilus Vaccines